bmiMD vs MEDVi: Which GLP-1 Provider Is Better?
A side-by-side comparison of bmiMD and MEDVi covering pricing, scores, medication types, insurance, and more to help you decide.
bmiMD
#13 of 31Budget-friendly GLP-1 platform offering both medication types at one of the lowest price points in the market.
Visit bmiMDMEDVi
#9 of 31Compounded GLP-1 platform offering both oral and injectable options with flexible dosing and affordable pricing.
Visit MEDVi| Feature | bmiMD | MEDVi |
|---|---|---|
| Our Score | 8.1/10 | 8.3/10 |
| Starting Price | $100/mo | $179/mo |
| Medication Type | Both | Compounded |
| Insurance Accepted | No | No |
| Best For | Budget-first users who want affordable GLP-1 access | Users who want a low entry price with oral and injectable compounded options |
| Ranking | #13 | #9 |
Pros & Cons Compared
bmiMD
Pros
- +Very affordable
- +Both medication types
- +Low barrier to entry
- +Quick process
Cons
- −Less comprehensive support
- −No insurance
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
MEDVi edges out bmiMD with a score of 8.3/10 vs 8.1/10. If budget is your priority, bmiMD starts at $100/mo compared to MEDVi's $179/mo. bmiMD offers both brand-name and compounded medications, giving you more flexibility. Choose bmiMD if you want: budget-first users who want affordable glp-1 access. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.